Back to Results

A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)

Interested in this Trial?

Contact Us

Trial Status Recruiting

Trial Identifier

NCT06305234

Condition

Phenylketonuria, Phenylketonuria (PKU)

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvaliase at the date of enrollment in Study 165-501 (prevalent-users) are eligible for participation in Study 165-503.

Eligibility Criteria

Birth Sex

All

Age

Any

Healthy Volunteers

No

Drug/Treatment:

Pegvaliase

Study Type:

Observational

Number of Participants:

200

Study Started:

2024-01-20

Study Updated:

2024-08-26

Trial Locations

  • University of Colorado

    Aurora, Colorado, United States

    Trial Status Recruiting

  • Northwestern University

    Chicago, Illinois, United States

    Trial Status Recruiting

  • Tulane University School of Medicine

    New Orleans, Louisiana, United States

    Trial Status Recruiting

  • Oregon Health & Science University

    Portland, Oregon, United States

    Trial Status Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, United States

    Trial Status Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas, United States

    Trial Status Recruiting

Inclusion Criteria

  • Subjects enrolled at US sites participating in the 165-501 study.

Exclusion Criteria

  • Legal incapacity or limited legal capacity without legal guardian representation.
  • Subject is unable or unwilling to provide informed consent for the additional interventional burden of the study (blood sampling).

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us